For heavily treatment-experienced adults with HIV-1 failing therapy. See Full Indication.
Access the resources below for additional details about RUKOBIA, including the challenges of people living with multidrug-resistant (MDR) HIV-1 who are failing their current therapy, its mechanism of action, information about the BRIGHTE trial, dosing and drug interactions, and the full Prescribing Information.
BRIGHTE Long-Term Data for RUKOBIA
~5-Year* Efficacy Results
Hear from Dr. Tony Mills on the exciting long-term data for RUKOBIA
RUKOBIA NATIONAL BROADCAST
On the panel are Dr. Bruce Gilliam,
Dr. Max Lataillade, Dr. Anthony Mills,
and Dr. Charlotte-Paige Rolle.
Virologic Data
See what panelists have to say about efficacy and safety data and what it could mean for people living with MDR HIV-1
Development of RUKOBIA
Hear a story of innovation, in which scientists discover a novel way to treat HIV in people living with MDR HIV-1
PEOPLE LIVING WITH MDR HIV-1
Get an overview of factors that define the people living with MDR HIV-1 and what might be causing multidrug resistance
Immunological Response
Watch practicing clinicians talk about CD4+ T-cell recovery in people living with MDR HIV-1 with advanced immunosuppression
BRIGHTE Educational Series
INTRODUCTION TO PEOPLE LIVING WITH MDR HIV-1
Consider challenges faced by people living with multidrug-resistant (MDR) HIV-1 with multidrug resistance and limited antiretroviral (ARV) options
NOVEL MECHANISM OF ACTION
Discover a first-in-class attachment inhibitor that prevents HIV-1 from interacting with host immune cells1-3
DOSING AND DRUG INTERACTIONS
Review recommended dosing, considerations for coadministration, and contraindications with RUKOBIA
Downloadable Resources
RUKOBIA PRESCRIBING INFORMATION
See the full Prescribing Information for RUKOBIA
ARV=antiretroviral.
References:
- Data on file, ViiV Healthcare.
- Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. US Department of Health and Human Services. Updated September 21, 2022. Accessed September 20, 2022.
https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adultadolescent-arv/guidelines-adult-adolescent-arv.pdf - Cahn P, Fink V, Patterson P. Fostemsavir: a new CD4 attachment inhibitor. Curr Opin HIV AIDS. 2018;13(4):341-345.
FSTWCNT220025
